Inhibition of Human Neutrophil Elastase with Peptidyl Electrophilic Ketones. 2. Orally Active PG-Val-Pro-Val Pentafluoroethyl Ketones
摘要:
Valylprolylvalyl pentafluoroethyl ketones with different N-protecting groups were evaluated in vitro and in vivo as inhibitors of human neutrophil elastase (HNE). Several of these compounds were found to be orally active in HNE-induced rat and hamster lung hemorrhage models. The compound with 4-(4-morpholinylcarbonyl)benzoyl as the protecting group, 71 (MDL 101,146), was studied in greater detail. Hydration and epimerization studies were performed on 71 and related compounds in various media, including human blood serum. Highperformance liquid chromatography studies on a reversed-phase system as a measure of the Lipophilicity of 71. and related compounds revealed a small range of relative retention times wherein the orally active compounds fell. The K-i value determined for 71 vs HNE was 25 nM.
PERFLUOROALKYL KETONE INHIBITORS OF ELASTASE AND PROCESSES FOR MAKING THE SAME
申请人:MERRELL PHARMACEUTICALS INC.
公开号:EP0763055B1
公开(公告)日:1999-11-03
US6008196A
申请人:——
公开号:US6008196A
公开(公告)日:1999-12-28
US6265381B1
申请人:——
公开号:US6265381B1
公开(公告)日:2001-07-24
[EN] PERFLUOROALKYL KETONE INHIBITORS OF ELASTASE AND PROCESSES FOR MAKING THE SAME<br/>[FR] INHIBITEURS D'ELASTASE AU PERFLUOROALKYLE CETONE ET PROCEDES DE PRODUCTION ASSOCIES
申请人:MERRELL PHARMACEUTICALS INC.
公开号:WO1995033762A1
公开(公告)日:1995-12-14
(EN) This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase, and to novel processes for making the same. As inhibitors of human neutrophil elastase, the compounds are useful in the treatment of a patient afflicted with a neutrophil associated inflammatory disease.(FR) Cette invention concerne des composés qui inhibent l'élastase, notamment l'élastase des polynucléaires neutrophiles humains, et de nouveaux procédés de production de ces inhibiteurs. Ces composés sont utiles comme inhibiteurs de l'élastase des polynucléaires neutrophiles humains dans le traitement d'un patient atteint d'une maladie inflammatoire associée aux polynucléaires neutrophiles.